Tight Glycemic Control in Diabetic Coronary Artery Bypass Graft Patients Improves Perioperative Outcomes and Decreases Recurrent Ischemic Events

Background—This study sought to determine whether tight glycemic control with a modified glucose-insulin-potassium (GIK) solution in diabetic coronary artery bypass graft (CABG) patients would improve perioperative outcomes. Methods and Results—One hundred forty-one diabetic patients undergoing CABG were prospectively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard therapy (serum glucose 250 mg/dL) using intermittent subcutaneous insulin beginning before anesthesia and continuing for 12 hours after surgery. GIK patients had lower serum glucose levels (138 4 versus 260 6 mg/dL; P 0.0001), a lower incidence of atrial fibrillation (16.6% versus 42%; P 0.0017), and a shorter postoperative length of stay (6.5 0.1 versus 9.2 0.3 days; P 0.003). GIK patients also showed a survival advantage over the initial 2 years after surgery (P 0.04) and decreased episodes of recurrent ischemia (5% versus 19%; P 0.01) and developed fewer recurrent wound infections (1% versus 10%, P 0.03). Conclusions—Tight glycemic control with GIK in diabetic CABG patients improves perioperative outcomes, enhances survival, and decreases the incidence of ischemic events and wound complications. (Circulation. 2004;109:1497-1502.)